Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001415889-25-002468
Filing Date
2025-01-31
Accepted
2025-01-31 16:07:34
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 11937
2 ex-1-01312025_090136.htm EX-1 3782
  Complete submission text file 0001415889-25-002468.txt   17540
Mailing Address C/O LOMOND THERAPEUTICS HOLDINGS, INC. 8 THE GREEN STE 8490 DOVER DE 19901
Business Address C/O LOMOND THERAPEUTICS HOLDINGS, INC. 8 THE GREEN STE 8490 DOVER DE 19901 561 464 2841
Lomond Therapeutics Holdings, Inc. (Subject) CIK: 0001900520 (see all company filings)

EIN.: 872959575 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-93945 | Film No.: 25578431
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 901 BATTERY STREET SAN FRANCISCO CA 94111
Business Address 901 BATTERY STREET SAN FRANCISCO CA 94111 415-610-4856
Yosemite Fund I, L.P. (Filed by) CIK: 0001970826 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G